PRINCETON, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 3, 2020– Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has…Original Article
FDA Approves Reblozyl (luspatercept-aamt) to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
